Design Therapeutics
DSGN
95 hedge funds and large institutions have $206M invested in Design Therapeutics in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 18 closing their positions.
75% more call options, than puts
Call options by funds: $28K | Put options by funds: $16K
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
20% more capital invested
Capital invested by funds: $172M → $206M (+$34.1M)
2.52% more ownership
Funds ownership: 56.57% → 59.1% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 100 → 95 (-5)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.49M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$3.24M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.22M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.16M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
-$1.85M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.68M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.52M |
| 4 |
Millennium Management
New York
|
-$1.12M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$621K |
DSGN Hedge Fund Activity: Q4 2024 in Review
95 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q4 2024, worth a combined $206M — up 20% from $172M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of DSGN and 15 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 34 added.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $4.49M. The largest seller was Prescott Group Capital Management, exiting entirely with an estimated $1.85M sold.
- 95 institutional investors held Design Therapeutics (DSGN) as of Q4 2024, down from 100 in Q3 2024.
- Funds reported $206M of Design Therapeutics stock for Q4 2024, up 20% quarter-over-quarter.
- 15 funds opened new Design Therapeutics positions in Q4 2024 and 18 closed out, a net change of -3 holders.
- The largest Design Therapeutics buyer in Q4 2024 was Driehaus Capital Management, an estimated $4.49M added.
- The largest Design Therapeutics seller in Q4 2024 was Prescott Group Capital Management, an estimated $1.85M sold.
Based on aggregated 13F filings for Q4 2024.